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Background: Esophageal dysmotility and gastroparesis are common secondary complications in patients with
diabetes mellitus. Patients with dysmotility express antibodies against gonadotropin-releasing hormone (GnRH) in
serum. The aim of the present study was to scrutinize patients with diabetes mellitus with regard to the presence
of GnRH antibodies, and to examine associations between antibodies and clinical findings.
Results: Thirty-nine consecutive patients with diabetes mellitus were included in the study after clinical examination
and examination by esophageal manometry and gastric emptying scintigraphy. Serum was analyzed for the presence
of antibodies against GnRH using an ELISA, and values are expressed as relative units (RU). Two age- and gender-
matched healthy subjects per each patient served as controls. The prevalence of IgM GnRH antibodies in patients
was 33% compared to 14% in controls (p = 0.027), with a higher antibody titer; 1.2 (0.6-5.0) and 0.2 (0.1-0.3) RU,
respectively (p = 0.000). The expression of IgG antibodies was 15% in patients and none in controls (p = 0.000). Lower
body mass index was associated with the presence of IgM antibodies (OR = 0.835, 95% CI = 0.699–0.998), and
autonomic neuropathy with the presence IgG antibodies (OR = 9.000, 95% CI = 1.327–61.025). Esophageal dysmotility
(69%) or gastroparesis (18%) were not associated with the presence of IgM antibodies (OR = 0.589, 95% CI = 0.143–
2.424 and OR = 3.407, 95% CI = 0.633–18.350, respectively). Neither was esophageal dysmotility associated with IgG
antibodies (OR = 2.500, 95% CI = 0.259–24.096).
Conclusions: Antibodies against GnRH are more common in patients with diabetes mellitus compared with
healthy controls. IgM antibodies are associated with lower body mass index and IgG antibodies are associated
with autonomic neuropathy.
Keywords: Autoantibodies, Diabetes mellitus, Esophageal dysmotility, Gastroparesis, Gonadotropin-releasing
hormone (GnRH), Secondary complicationsBackground
Gastrointestinal dysmotility is a common disorder in
the population, especially as a complication secondary to
diabetes mellitus [1-3]. Recently, we have shown that 63%
of patients with diabetes mellitus suffer from esophageal
dysmotility and 13% from gastroparesis [4]. Although
some patients suffer from gastrointestinal symptoms, such* Correspondence: bodil.ohlsson@med.lu.se
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reproduction in any medium, provided the oras regurgitation, vomiting, and abdominal fullness and
bloating after eating, the associations between symptoms
and objective findings are poor [2-4]. The etiology of
gastrointestinal dysmotility needs to be elucidated. Dam-
age to interstitial cells of Cajal, loss of neuronal nitric
oxide expression, hyperglycemia, vagal or autonomic neur-
opathy, myopathy, and abnormalities in plasma levels of
several hormones have been proposed [1,5].
Gonadotropin-releasing hormone (GnRH) is known to
bind to specific receptors on the pituitary, controlling the
secretion of the gonadotropins [6,7]. However, there isal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Berntorp et al. BMC Research Notes 2013, 6:329 Page 2 of 8
http://www.biomedcentral.com/1756-0500/6/329growing evidence for its role as a neurotransmitter in the
enteric nervous system (ENS) [8], where it has been
shown to inhibit gastric secretion and gastrin release [9],
stimulate enteric motility [10,11], and inhibit cell prolifera-
tion in gastric epithelial and smooth muscle cells [12,13].
We have recently shown that treatment with GnRH in
man and rats may lead to loss of enteric neurons, with en-
suing development of gastroparesis and severe dysmotility
[14,15]. Antibodies against GnRH have been observed in
patients with irritable bowel syndrome (IBS), motility dis-
orders, diabetes mellitus, and patients with functional
bowel symptoms secondary to primary Sjögren’s syn-
drome. Patients with organic gastrointestinal diseases such
as inflammatory bowel disease, celiac disease, and sclero-
derma did not express GnRH antibodies [16,17]. Thus, pa-
tients with diabetes mellitus frequently express antibodies
against GnRH and secondary esophageal dysmotility, but
the association between these two findings has to date not
been examined [4,17]. The aim of the present study was
therefore to further examine the prevalence of antibodies
against GnRH in patients with diabetes mellitus, with or
without esophageal dysmotility or gastroparesis, to further
characterize the role of the antibodies and to search for
possible associations with clinical findings.
Methods
This study was performed according to the Helsinki
Declaration and was approved by the Regional Ethics
Review Board of Lund University. All subjects gave their
written, informed consent before entering the study.
Patients
The inclusion criterion of the study was diabetes mellitus
in patients above 18 years of age. The first patient at each
consultation occasion who fulfilled this criterion when
scheduled for routine clinical follow-up at the Department
of Endocrinology, Skåne University Hospital, Malmö, from
January 2008–February 2010, was invited to participate in
the study. Exclusion criteria were severe renal failure de-
manding dialysis or severe cardiac diseases. At the time of
the inclusion, they completed an established questionnaire
with 15 symptoms related to disturbances of the gastro-
intestinal tract (loss of appetite, swallowing disturbances,
meal-related cough, early satiety, nausea, vomiting, weight
loss, abdominal fullness, bloating, regurgitation, constipa-
tion, diarrhea, evacuation incontinence, symptomatic post-
prandial hypoglycemia and postprandial perspiration),
previously used for these patients [2-4]. Types and dur-
ation of diabetes mellitus, presence of diabetes complica-
tions such as retinopathy (based on fundus photography),
angiopathy, microalbuminuria (measured as the albumin/
creatinin quotient), albuminuria, peripheral neuropathy
(examined by patellar and achilles tendon reflexes, sensi-
tivity to vibration and monofilament test), autonomicneuropathy according to established clinical criteria (sexual
dysfunction, profound sweating and orthostatic blood pres-
sure), drug treatments, concomitant diseases, and body
mass index (BMI) were all recorded by the physicians.
Glycosylated hemoglobin (HbA1c) was analyzed at
the Department of Chemistry, according to clinical rou-
tines. HbA1c values were collected as Mono-S and sub-
sequently converted to the National Glycohemoglobin
Standardization Program (NGSP) standard by use of the
following algorithm: 0.923 x HbA1c (Mono-S) × 1.345 =
HbA1c (NGSP) [18]. Percentage HbA1c values were
converted to the International Federation of Clinical
Chemistry (IFCC) standard in mmol/mol according to
the following equation: IFCC (mmol/mol) = ([NGSP
(%)] - 2,152)/0.09148 [18].
The patients were referred to investigations by esopha-
geal manometry and gastric emptying scintigraphy. If both
examinations could not be performed, the patient was ex-
cluded from the study. Patients were also referred to
esophagogastroduodenoscopy when clinically indicated.
Thirty-nine patients of the 55 invited completed the
study and provided blood samples for analysis of GnRH
antibodies, and were thus finally included in the evalu-
ation. The most common reason not to complete the
study was an inability to swallow the manometry catheter.
Esophageal manometry
Standardized esophageal manometry was performed with
an intraluminal, solid-state transducer system (Gaeltec
Ltd, Isle of Skye, Scotland). Polygraph ID converter digi-
tized the analog signal. The software was PolyGram NET
(Medtronic-SynMed Medical, Stockholm, Sweden). All
pressure values were expressed in mmHg and referred to
atmospheric pressure. The manometry catheter was intro-
duced through the nose and fluoroscopically positioned in
the distal esophagus with the patient sitting in an upright
position, which is the standard method at our laboratory.
With the catheter in place, all participants were instructed
to swallow 10 ml of a barium contrast medium (60% w/v).
At least five barium swallows were recorded. The video
fluoroscopic image and the manometry registration were
mixed using a video output card (Medtronic-SynMed
Medical) [2,3]. Patients who fulfilled one or more of the
following five criteria in the esophageal manometry with
abnormal results were considered to suffer from eso-
phageal dysmotility: 1: Absence of peristaltic contraction
in the esophagus (aperistalsis > 0%), 2: Mean peristaltic
contraction amplitude < 30 or > 200 mmHg in the esopha-
gus, 3: Percentage of simultaneous, non-propulsive peri-
staltic waves in the esophagus > 10%, 4: Speed of the
peristaltic wave < 3 or > 6 cm/s in the distal esophagus,
and 5: Resting pressure in the lower esophageal sphinc-
ter (LES) < 10 or > 30 mmHg. Normal peristaltic activity
was defined as propulsive contraction waves with peak
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tween 3–6 cm/s [2,3,19,20].
Gastric emptying scintigraphy
A test meal was prepared by adding tin colloid labeled
with 30–50 Mbq of technetium-99 to an egg, which was
whipped in a glass cup in a hot water bath until coagu-
lated. The egg and a slice of toasted white bread were
cut into pieces smaller than 1 cm × 1 cm and served
with 100 ml water at 37°C. The meal was eaten within
5 min. Immediately thereafter, a large-field, double-
headed gamma camera (Philips Skylight, Philips Medical
Systems, Best, The Netherlands) was placed anteriorly
and posteriorly parallel to the upper abdominal wall.
The radioactivity was measured continuously (1-min
frames) for 70 min starting immediately after meal in-
gestion. A Region of Interest (ROI) representing the
stomach was created and the activity of the first frame
was taken as 100%. The gradual decreasing radioactivity,
measured as the number of radioactivity decays per mi-
nute (counts/min), was plotted against time. The time
elapsed to reach a 50% decrease of the activity in the
ROI (T50) was identified as the point at which this plot
crossed the 50% value. The values of the radioactivity
measured were corrected for the half-life of 99mTc, and
for attenuation by using the geometrical mean values of
the decay curves obtained from the two gamma camera
heads used. T50 > 2 standard deviations (SD) for healthy
control subjects (70 min) was considered abnormal [21].
Measurement of human antibodies against gonadotropin-
releasing hormone
Blood samples were drawn from patients and the serum
was separated and kept frozen at -20°C until analyzed.
Analysis of anti-GnRH antibodies was carried out by an
ELISA slightly modified on the basis of the results de-
scribed in previous studies [8,16]. The wells of micro titer
plates were coated with human GnRH (L7134, Sigma, St
Louis, MO, USA) for an overnight incubation at 4°C and
thereafter the plastic wells were blocked with 0.5% fish gel
solution (G7765, Sigma) in PBS containing 0.05% Tween-
20 (PBS-T). Serial dilutions of patient serum (1/100, 1/500
and 1/2500 in PBS-T) were then added to the plates and
incubated for 2 h at room temperature (RT) and overnight
at 4°C. After rinsing with PBS-T, deposition of autoanti-
bodies directed to GnRH was detected using biotinylated
rabbit anti-human IgM (673211, MP Biomedicals, Solon,
OH, USA) or IgG antibodies (ab7159, ABcam, Cambridge,
MA, USA) appropriately diluted in PBS-T. After another
incubation for 2 h at RT, the plates were washed and
the bound, biotinylated antibodies detected by alkaline
phosphatase-conjugated streptavidin (405211, Biolegend,
San Diego, CA, USA), incubated for 1 h at RT. To develop
a color reaction a phosphatase substrate kit (37620, Pierce,Rockford, Ill, USA) was used. The absorbance at 405 nm
was measured after 2 h of incubation at RT. A plasma
pool from healthy blood donors was included on each
ELISA plate for measurements of the variation. The
plasma pool was used for the calculation of the intra-assay
and inter-assay coefficient of variation, which was 11.5%
and 16.1%, respectively, for IgM and 11.5% and 25.4%, re-
spectively, for IgG. Antibody levels are presented as rela-
tive units (RU) (absorbance values after subtraction of
background levels and multiplied by 100). Relative units
over 0 were considered as a positive antibody level [17].
The controls were chosen from a cohort of healthy
blood donors previously described in detail [17]. Over a
period of five months (October 1996–February 1997),
blood donors were offered antibody screening for gastro-
intestinal diseases. To be able to include all blood do-
nors in Malmo, sera from male donors were collected
over a 3-month period and from female donors over a
4-month period (in accordance with their regular dona-
tion intervals). A total of 1,970 donors were included.
During this period, 2,135 blood donations took place,
which means that at least 92% of donors agreed to be in-
cluded. From this sample cohort, 50 men and 50 women
from each 10-year age span period, between 20 and
70 years of age, were randomly included. As few blood
donors above 60 years of age, only 16 women and 40
men were included in the age group 60–70 years. In
total, 456 controls were examined during the same time
period as the patients. From this cohort, two age- and
gender-matched controls were randomly extracted for
each patient in this study.
Statistical analyses
The data were analyzed using the statistical software
package SPSS for Windows© (Release 20.0; IBM). All
variables were analyzed for normal distribution by
Kolmogorov-Smirnov test. Group-wise differences be-
tween patients and controls were tested by using the un-
paired Student’s t-test and, when normality was rejected
(antibody levels), the Mann-Whitney U-test was used.
Fisher’s exact test was used for dichotomized variables.
Correlations were calculated by Spearman rank correl-
ation test. Values are expressed as mean ± standard devi-
ation (SD) or median, interquartile range (IQR). Binary
logistic regression analysis was performed to test for an as-
sociation between the presence of antibodies against
GnRH (dependent variable) and clinical findings in
patients. Independent variables were age (years), gender,
type of diabetes, duration of disease (years), BMI (kg/m2),
HbA1c (mmol/mol), esophageal and gastric dysmotility,
secondary complications, and symptoms, examined as
univariate analysis. No presence of antibodies, symptoms
or pathological findings was used as reference. P < 0.05
was considered statistically significant.
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Patient characteristics
Thirty-nine patients with diabetes mellitus (27 females),
age 52.4 ± 12.5 years, were included. All the patients
were insulin-treated, and were in acceptable metabolic
control (Table 1). Esophageal dysmotility was more
common (69%) than gastroparesis (18%). Retinopathy
was the most common diabetes complication (72%)
(Table 1). Although the patients were included regard-
less of the presence of gastrointestinal symptoms, theTable 1 The associations between characteristics in patients w
against gonadotropin-releasing hormone (GnRH) in serum
Patients
(N = 39)
Age (years) 52.4 ± 12.5
Gender (Female/male) n (%) 27(69)/12(31)
Type of diabetes (1/2) 36/3
Duration of the disease (years) 26.3 ± 13.1
BMI (kg/m2) 26.5 ± 5.8
HbA1c (mmol/mol) 65.9 ± 9.9
Esophageal dysmotility n (%)
No (reference) 12 (31)
Yes 27 (69)
Gastric dysmotility n (%)
No (reference) 32 (82)
Yes 7 (18)
Retinopathy n (%)
No (reference) 11 (28)
Yes 28 (72)
Angiopathy n (%)
No (reference) 26 (67)
Yes 13 (33)
Microalbuminuria n (%)
No (reference) 35 (90)
Yes 4 (10)
Macroalbuminuria n (%)
No (reference) 36 (92)
Yes 3 (8)
Autonomic neuropathy n (%)
No (reference) 29 (74)
Yes 10 (26)
Peripheral neuropathy n (%)
No (reference) 20 (51)
Yes 19 (49)
BMI Body mass index, HbA1c Glycosylated hemoglobin. Values are given as mean ±
calculations not possible to carry out due to a low number of patients. In the statis
(reference) antibodies.majority of patients reported some sort of symptoms re-
lated to the gastrointestinal tract and food intake (Table 2).
Antibodies against gonadotropin-releasing hormone
The prevalence of IgM antibodies in patients with diabetes
mellitus was 33%, to be compared with 14% in controls
(p = 0.027), with a higher titer level in the patients (p =
0.000). The prevalence of IgG antibodies in patients was
15% and none in the controls (p = 0.000) (Table 3). There
was no association between the expression of IgM andith diabetes mellitus and the presence of antibodies
GnRH IgM −/+ GnRH IgG −/+
OR, 95% CI OR, 95% CI
1.469 (0.927-1.034) 0.019 (0.964–1.127)
1.696 (0.413-1.976) 2.667 (0.452–15.722)
1.00 (0.082–12.164) 3.100 (0.235–40.895)
0.654 (0.940–1.042) 0.048 (0.974–1.126)
0.835 (0.699–0.998) 1.103 (0.958–1.269)
0.983 (0.917–1.053) 0.968 (0.880–1.063)
1.000 1.000




0.829 (0.192–3.577) 2.174 (0.224–21.079)
1.000 1.000




4.545 (0.372–55.542) 3.100 (0.235–40.895)
1.000 1.000
1.481 (0.334–6.572) 9.000 (1.327–61.025)
1.000 1.000
0.857 (0.226–3.254) 1.062 (0.187–6.052)
standard deviation (SD) or n (%). OR Odds ratio, CI Confidence interval, - =
tical calculations, patients were divided into those with and without
Table 2 The association between various symptoms in patients with diabetes mellitus and the presence of antibodies
against gonadotropin-releasing hormone (GnRH) in serum
Symptoms Patients (N = 39) GnRH IgM −/+ GnRH IgG −/+
n (%) OR, 95% CI OR, 95% CI
Loss of appetite
No (reference) 31 (80) 1.000 1.000
Yes 8 (20) 4.792 (0.928–24.750) 0.743 (0.074–7.436)
Swallowing disturbances
No (reference) 32 (82) 1.000 1.000
Yes 7 (18) 0.764 (0.127–4.596) 0.900 (0.088–9.178)
Meal-related cough
No (reference) 33 (85) 1.000 1.000
Yes 6 (15) 1.000 (0.158–6.330) 3.625 (0.494–26.611)
Early satiety
No (reference) 24 (62) 1.000 1.000
Yes 15 (38) 0.606 (0.148–2.486) 0.769 (0.123–4.821)
Nausea
No (reference) 28 (72) 1.000 1.000
Yes 11 (28) 0.343 (0.062–1.898) 0.460 (0.047–4.460)
Abdominal fullness
No (reference) 23 (59) 1.000 1.000
Yes 16 (41) 0.300 (0.067–1.347) 0.240 (0.025–2.286)
Bloating
No (reference) 19 (49) 1.000 1.000
Yes 20 (51) 0.278 (0.067–1.147) 0.941 (0.165–5.361)
Regurgitation
No (reference) 27 (69) 1.000 1.000
Yes 12 (31) 0.114 (0.013–1.009) 2.667 (0.452–15.722)
Constipation
No (reference) 28 (72) 1.000 1.000
Yes 11 (28) 0.675 (0.145–3.135) 0.460 (0.047–4.460)
Diarrhea
No (reference) 33 (85) 1.000 1.000
Yes 6 (15) 1.000 (0.158–6.330) 1.120 (0.107–11.726)
Symptomatic postprandial hypoglycemia
No (reference) 30 (77) 1.000 1.000
Yes 9 (23) 0.764 (0.127–4.596) 0.900 (0.088–9.178)
Postprandial perspiration
No (reference) 34 (87) 1.000 1.000
Yes 5 (13) 1.394 (0.203–9.585) 1.450 (0.133–15.793)
n number, OR Odds ratio, CI Confidence interval. In the statistical calculations, patients were divided into those with and without (reference) antibodies.
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bodies were found in 17 of 39 patients (44%) compared
with 11 of 78 controls (14%) (p = 0.001). None of the sec-
ondary complications or symptoms was associated with
the presence of IgM antibodies (Tables 1 and 2). Theprevalence of vomiting (n = 2), weight loss (n = 1), and
evacuation incontinence (n = 2) was too low to allow cal-
culations. The only variable associated with IgM anti-
bodies was BMI, with lower BMI being associated with
an increased prevalence of antibodies (OR = 0.835, 95%
Table 3 Levels of antibodies against gonadotropin-






N = 39 n = 78
Prevalence IgG antibodies n (%) 6 (15) 0 0.000
Level of IgG antibodies (RU) 2.4 (0.4-1.9) * -
Prevalence IgM antibodies n (%) 13 (33) 11 (14) 0.027
Level of IgM antibodies (RU) 1.2 (0.6-5.0) 0.2 (0.1-
0.3)
0.000
Antibody levels are presented as relative units (RU), median (interquartile
range). n (%) = number and percentage of subjects. * = no IgG antibodies
were found. Mann-Whitney U- test or Fisher’s exact test. P < 0.05 was
considered statistically significant.
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the only variable associated with IgG antibodies (OR= 9.000,
95% CI = 1.327–61.025). Esophageal dysmotility or gastro-
paresis were not associated with the presence of IgM anti-
bodies (OR = 0.589, 95% CI = 0.143–2.424 and OR = 3.407,
95% CI = 0.633–18.350, respectively). Neither was esopha-
geal dysmotility associated with the presence of IgG anti-
bodies (OR = 2.500, 95% CI = 0.259–24.096). Association
between gastroparesis and the presence of IgG antibodies
was not able to calculate (Table 1). There were no differ-
ences in gastric emptying rate or age between patients
who did or did not express IgM or IgG antibodies
(p = 0.059 vs. p = 0.538 and p = 0.466 vs. p = 0.303, respect-
ively). There was no correlation between the level of IgM
or IgG antibodies and gastric emptying rate (p = 0.602 and
p = 0.700, respectively). Neither did the level of IgM
or IgG antibodies correlate to esophageal aperistalsis
(p = 0.268 and p = 0.518, respectively), mean peristaltic con-
traction amplitude (p = 0.275 and p = 0.156, respectively),
percentage of simultaneous, non-propulsive peristaltic
waves (p = 0.955 and p = 0.441, respectively), speed of the
peristaltic wave (p = 0.603 and p = 0.493, respectively)
or resting pressure in the lower esophageal sphincter
(p = 0.562 and p = 0.827, respectively).
Discussion
The present study showed that patients with diabetes
mellitus expressed antibodies against GnRH in serum.
The result confirms previous findings of presence of
GnRH antibodies in patients expressing a high preva-
lence of gastrointestinal symptoms and dysmotility and/
or diabetes mellitus [17]. Apart from a weak association
between the presence of IgM antibodies and lower BMI,
and an association between the presence of IgG anti-
bodies and autonomic neuropathy, no other associations
with the antibody expression were found.
Gonadotropin-releasing hormone is secreted by the
hypothalamus and its most important effect is on the
pituitary, stimulating gonadotropin synthesis and secretion.It is a crucial hormone in reproductive physiology and
sexual behavior [6]. Peripherally, GnRH and GnRH recep-
tors have been found in the rat myenteric plexus and the
intestinal epithelium [22,23], and GnRH has been de-
scribed in human myenteric neurons [8]. Gonadotropin-
releasing hormone has been shown to inhibit the release
of gastric secretion and gastrin release in dog [9], and to
stimulate motor function in the gastrointestinal tract in
female rats and in a patient suffering from chronic intes-
tinal pseudo-obstruction [10,11]. Furthermore, GnRH
antibodies have been shown to have anti-proliferative ef-
fects on epithelial and smooth muscle cells [12,13] and
gastrointestinal tumor cell lines [24,25]. In another study,
the GnRH receptor has been found on murine endomet-
rium mediating apoptosis [26]. Thus, GnRH may affect
growth regulation of gastrointestinal structures.
We have now repeatedly described that patients with
IBS and dysmotility express GnRH antibodies [8,16,17],
but the effect of GnRH and/or its antibodies on the
physiology and pathophysiology of the gastrointestinal
tract remains to be determined. In our previous report,
the titer of antibodies, but not the prevalence, was higher
in patients compared with controls [17]. This is in con-
trast with the present findings of an increased preva-
lence of antibodies in relation to diabetes mellitus. This
discrepancy may be explained by the low number of
patients examined in the former study, with a greater
percentage of females (20 patients, 11 females) [17].
Nevertheless, there was an enhanced expression of
GnRH antibodies in both studies in relation to diabetes
mellitus. A recent report showed a significant effect of
the intestinal GnRH mRNA level on blood glucose
levels, indicating that GnRH may be of importance for
glucose homeostasis [27]. Moreover, development of
diabetes mellitus and autoimmune thyroiditis has been
reported after long-term administration of GnRH [28].
In the present study, lower BMI in diabetes mellitus was
associated with the expression of IgM antibodies. We have
little knowledge about the exact mechanisms of appetite
and body weight regulation, but a range of different pep-
tide hormones and neuropeptides seems to be involved
[29]. It is recognized that appropriate regulation of repro-
duction, energy intake, and energy expenditure, and thus
maintenance of body weight and fertility, relies on com-
plex hypothalamic neurocircuitry [30]. Food intake and
the reproductive function are closely linked. The presence
of autoantibodies against melanocyte-stimulating hormone
has been documented in healthy man and rat. These anti-
bodies, and other autoantibodies, could be involved in the
regulation of feeding, but could also influence the level of
anxiety. The authors conclude that autoantibodies against
appetite-regulating neuropeptides and peptide hormones
may be important participants in mechanisms controlling
appetite and food intake [31]. Antibodies against GnRH
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thetically affect appetite-regulating structures in the hypo
thalamus. Furthermore, the peripheral release of appetite-
regulating neuropeptides and peptide hormones from the
gastrointestinal tract may be regulated by GnRH present
in the ENS [8,22,23,32].
Repeated treatment with GnRH has been shown to
render enteric dysmotility and antibodies against GnRH
in serum in some cases [14]. The antibodies are assumed
to be secondary to the dysmotility, reflecting neuronal
damage [14]. Gastrointestinal dysmotility is associated
with autonomic neuropathy [33]. Thus, the association
between IgG antibodies and autonomic neuropathy in
this study may reflect an association between gastro-
intestinal neuron damage in ENS and autonomic neur-
opathy. On the contrary, a few studies have reported the
presence of antibodies in serum in patients with auto-
nomic neuropathy, so the antibodies may reflect neur-
onal damage in the autonomic nervous system as well
[34,35]. We do not know the difference between the ex-
pression of IgM and IgG antibodies in the patients with
diabetes mellitus. Probably, the expression of IgM anti-
bodies is persisting in this entity, as the patients had had
duration of diabetes mellitus for several years, before in-
clusion in the study.
One of the limitations of this study is the small sam-
ple size. However, we need to perform small pilot stud-
ies before testing our hypothesis in greater cohorts
with hundreds of patients. Another limitation is that
the motility of the lower gastrointestinal tract was not
examined, and that the manometry was carried out
only over a short time span. If an ambulatory manom-
etry for 24 h had been used, associations may have been
found. We chose to examine the patients with as few ex-
aminations as possible, to diminish the burden on the pa-
tients, and to be able to include more patients. In future
studies, it seems more relevant to focus on esophageal
manometry examination than on gastric emptying scintig-
raphy, which seems to be a smaller problem among these
patients. The test method needs to be further evaluated
concerning the optimal cut-off level. In our ELISA, we
considered all relative antibody units above zero as expres-
sion of antibodies. If a higher baseline level of antibodies
present in serum had been regarded as expression, almost
all controls would have been below this cut-off. When
more patients have been studied, the cut-off level for posi-
tive expression should be redefined.
Conclusions
Patients with diabetes mellitus express antibodies against
GnRH in serum. Apart from weak associations between
the presence of IgM antibodies and lower BMI, and IgG
antibodies and autonomic neuropathy, no other associa-
tions with the antibody expression are found.Availability of supporting data
The data supporting the results of this article is included
within the article.
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